Source: Getty Images Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder cancer, according to Thomas Powles, MBBS ...
Consolidation durvalumab is underutilized in unresectable stage III NSCLC, with only 61.5% of eligible patients receiving it post-cCRT. Patients receiving durvalumab after cCRT show improved ...